|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2009-11-25
|
|
pubmed:abstractText |
Blockade of the renin-angiotensin-aldosterone system (RAAS) does not completely prevent progression of renal disease. Mineralocorticoid receptor blockade provides additional renoprotection over ACE-inhibition monotherapy. We examined the mechanisms underlying superior renoprotection in the subtotal nephrectomy (SNX) model.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1460-2385
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3640-51
|
|
pubmed:meshHeading |
pubmed-meshheading:19666910-Aldosterone Antagonists,
pubmed-meshheading:19666910-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:19666910-Animals,
pubmed-meshheading:19666910-Drug Therapy, Combination,
pubmed-meshheading:19666910-Kidney Diseases,
pubmed-meshheading:19666910-Male,
pubmed-meshheading:19666910-Podocytes,
pubmed-meshheading:19666910-Rats,
pubmed-meshheading:19666910-Rats, Sprague-Dawley,
pubmed-meshheading:19666910-Spironolactone,
pubmed-meshheading:19666910-Tetrahydroisoquinolines
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to monotherapies--the effect on podocytes.
|
|
pubmed:affiliation |
Department of Pathophysiology, Semmelweis University, Budapest, Hungary.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
